Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cardiac stem cell therapies inch toward clinical litmus test

Nature Biotechnology volume 31, pages 5–6 (2013)Cite this article

Subjects

The challenges of developing cell therapies are manifold. The technology remains immature, and scientists' understanding of the underlying biology remains incomplete. “Overall it's still in an experimental state, absolutely no question about it,” says Andreas Zeiher, professor of medicine at the Goethe University in Frankfurt, Germany, who is leading a long-term study evaluating 1,500 patients who have undergone bone marrow–derived cell therapy for cardiac disease at his institution during the past decade. “In cardiovascular disease you need treatments with hard endpoints,” he says.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sheridan, C. Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol 31, 5–6 (2013). https://doi.org/10.1038/nbt0113-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0113-5

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing